nanoTox, the first company to provide complete risk analysis and profiling exclusively for nanoparticles, announced today that Professor Michael Depledge has joined its Scientific Advisory Board. A leading specialist in the impact of the environment on human health and wellbeing, Depledge holds a Chair in Environment and Human Health at the Peninsula Medical School in Devon, UK. He also is a commissioner for the Royal Commission on Environmental Pollution.
"We are honored to have Professor Depledge join us as we work to ensure nanotechnology products and processes are safely developed." said Harry Bushong, president of nanoTox. "His expertise in environmental and medical toxicology is internationally recognized and he will be a valuable resource for nanoTox and our clients."
Depledge was awarded a doctor of science degree by the University of London in recognition of major scientific contributions to the fields of comparative toxicology and medical toxicology. He is an expert advisor on marine pollution to the United Nations, working in Brazil, Costa Rica, India, Vietnam and several other countries to develop the Rapid Assessment of Marine Pollution program for the UN's Global Oceans Observing System. He also is an expert advisor to the World Health Organization.
Depledge was the founding director of the Plymouth Environmental Research Centre in 1996. In 2002, he became the chief scientific advisor of the UK's Environment Agency where he produced the agency's first science strategy and created a Europe-wide partnership among the science departments of EU member state environment agencies. Depledge is a former founding board member of Natural England and visiting professor at the Department of Zoology, Oxford University, and the School of Earth Sciences and Engineering, Imperial College, London. He is strategic advisor to the vice chancellor of the University of Westminster.
Depledge was educated at Westfield College, University of London, where he gained a first-class honors degree in Biological Sciences and a PhD in the toxicology of marine organisms. As a post-doctoral research fellow at the Brompton Hospital, London, he studied lung damage in the severely ill. Later, as a clinical scientist at the Royal Marsden Hospital, he investigated toxicity associated with whole-body irradiation and bone-marrow transplantation used in the treatment of leukemia.
Located in Austin, Texas, nanoTox (www.nanotox.com) is the first company to provide complete assessment - and solutions - exclusively for nanoparticles. nanoTox determines the toxicity of its clients' nanoproducts and offers strategies for managing, reducing or eliminating risk to meet state and federal safety guidelines and shorten time to market. Because nanoTox uses methodologies that are performed under recognized international data quality standards (GLP, ISO, etc.) in its laboratories, the results and associated assessments are suitable for use to support regulatory decisions, product registrations, litigation and for acceptance by the insurance industry.
nanoTox ensures complete client confidentiality for all of its clients, which include companies or entities that require government approval to market their nanoproducts, venture capital firms that invest in nanoproduct companies, law firms engaged by such companies and insurance companies considering insuring such companies from liability.